Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …

Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …

Background Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-
receptor–signaling pathway, the major driver of prostate-cancer growth. We aimed to …

It is unclear whether a single clone metastasizes and remains dominant over the course of
lethal prostate cancer. We describe the clonal architectural heterogeneity at different stages …

Despite new treatments for castrate-resistant prostate cancer (CRPC), the prognosis of
patients with CRPC remains bleak due to acquired resistance to androgen receptor (AR) …

Prostate cancer resistance to castration occurs because tumours acquire the metabolic
capability of converting precursor steroids to 5α-dihydrotestosterone (DHT), promoting …

Background Androgen receptor (AR) signalling remains critically important in metastatic
castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III trials …

Purpose Enzalutamide resistance could result from raised androgens and be overcome by
combination with abiraterone acetate. PLATO (ClinicalTrials. gov identifier: NCT01995513) …

Signaling networks play key homeostatic processes in living organisms but are commonly
hijacked in oncogenesis. Prominent examples include genetically altered receptor tyrosine …

Background Abiraterone acetate and enzalutamide both improve outcomes in patients with
metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these …